MIT Validates Serva Energy’s Novel Production Method of Life-saving Actinium-225 Isotope

Serva Energy’s sample measurement of the rare, cancer-killing medical isotope Actinium-225 has been validated by the Massachusetts Institute of Technology (MIT) Nuclear Research Laboratory.

It’s the latest milestone in Serva’s development of commercial quantities of Actinium-225 (Ac-225) needed for next-generation Targeted Alpha Therapies.Continue reading

C-Path and CHI Announce Data Sharing Agreement

TUCSON, Ariz., October 26, 2023 — Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI), a leading nonprofit dedicated to improving the lives of children and adults living with Congenital Hyperinsulinism (HI), today announced a data sharing agreement to incorporate rare disease patient-level data from CHI’s HI Global Registry into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading

City of Hope, TGen awarded five-year, $4.5 million grant to advance liquid biopsy for pancreatic cancer

  • City of Hope-led consortium seeks to validate noninvasive screening test for pancreatic ductal adenocarcinoma through large-scale cohort
  • Inclusion of diverse populations is crucial for advancing understanding of these diseases, promoting health equity, and ensuring that medical research and treatments are inclusive and effective for all populations

Continue reading

HonorHealth Research Institute, City of Hope and TGen lead international team in creating ‘robust’ early-detection method for pancreatic cancer

SCOTTSDALE, Ariz. — Oct. 18, 2023 — In a significant breakthrough that could eventually extend the survival of patients with one of the deadliest of all malignancies, an international team of researchers have devised an investigational blood test that might one day help doctors detect pancreatic cancer earlier.Continue reading